Literature DB >> 10963369

Distribution of chromogranin B-like immunoreactivity in the human hippocampus and its changes in Alzheimer's disease.

J Marksteiner1, T Lechner, W A Kaufmann, P Gurka, C Humpel, C Nowakowski, H Maier, K A Jellinger.   

Abstract

Synapse loss is crucially involved in cognitive decline in Alzheimer's disease (AD). This study was performed to investigate the distribution and density of chromogranin B-like immunoreactivity in the hippocampus of control compared to AD brain. Chromogranin B is a large precursor molecule found in large dense-core vesicles. For immunocytochemistry we used an antiserum raised against a synthetic peptide (PE- 11) present in the chromogranin B molecule. Chromogranin B-like immunoreactivity was concentrated in the terminal field of mossy fibers, the inner molecular layer of the dentate gyrus and in layer II of the entorhinal cortex. In AD, chromogranin B was detected in neuritic plaques. The density of chromogranin B-like immunoreactivity was significantly reduced in the inner molecular layer of the dentate gyrus and in layers II, III and V of the entorhinal cortex in AD brains. The present study demonstrates that chromogranin B is a marker for human hippocampal pathways. It is particularly suitable for studying nerve fibers terminating at the inner molecular layer of the dentate gyrus. It is present in neuritic plaques, and its density is reduced in a layer-specific manner.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10963369     DOI: 10.1007/s004010000239

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  10 in total

Review 1.  Chromogranins A and B as regulators of vesicle cargo and exocytosis.

Authors:  José D Machado; Jésica Díaz-Vera; Natalia Domínguez; Carmen M Alvarez; Marta R Pardo; Ricardo Borges
Journal:  Cell Mol Neurobiol       Date:  2010-11-03       Impact factor: 5.046

2.  Synaptic proteins in Alzheimer's disease.

Authors:  Josef Marksteiner; Walter A Kaufmann; Peter Gurka; Christian Humpel
Journal:  J Mol Neurosci       Date:  2002 Feb-Apr       Impact factor: 3.444

3.  Astrocyte Transcriptome from the Mecp2(308)-Truncated Mouse Model of Rett Syndrome.

Authors:  Chloé Delépine; Juliette Nectoux; Franck Letourneur; Véronique Baud; Jamel Chelly; Pierre Billuart; Thierry Bienvenu
Journal:  Neuromolecular Med       Date:  2015-07-25       Impact factor: 3.843

4.  Inositol 1,4,5 trisphosphate receptor and chromogranin B are concentrated in different regions of the hippocampus.

Authors:  Nils H Nicolay; Daniel Hertle; Wolfgang Boehmerle; Felix M Heidrich; Mark Yeckel; Barbara E Ehrlich
Journal:  J Neurosci Res       Date:  2007-07       Impact factor: 4.164

5.  Chromogranin B gene ablation reduces the catecholamine cargo and decelerates exocytosis in chromaffin secretory vesicles.

Authors:  Jésica Díaz-Vera; Yézer G Morales; Juan R Hernández-Fernaud; Marcial Camacho; Mónica S Montesinos; Federico Calegari; Wieland B Huttner; Ricardo Borges; José D Machado
Journal:  J Neurosci       Date:  2010-01-20       Impact factor: 6.167

6.  Neurodegeneration and neuroinflammation in cdk5/p25-inducible mice: a model for hippocampal sclerosis and neocortical degeneration.

Authors:  David Muyllaert; Dick Terwel; Anna Kremer; Kristina Sennvik; Peter Borghgraef; Herman Devijver; Ilse Dewachter; Fred Van Leuven
Journal:  Am J Pathol       Date:  2008-01-17       Impact factor: 4.307

7.  Striatal alterations of secretogranin-1, somatostatin, prodynorphin, and cholecystokinin peptides in an experimental mouse model of Parkinson disease.

Authors:  Anna Nilsson; Maria Fälth; Xiaoqun Zhang; Kim Kultima; Karl Sköld; Per Svenningsson; Per E Andrén
Journal:  Mol Cell Proteomics       Date:  2009-01-08       Impact factor: 5.911

8.  Chromogranin B: intra- and extra-cellular mechanisms to regulate catecholamine storage and release, in catecholaminergic cells and organisms.

Authors:  Kuixing Zhang; Nilima Biswas; Jiaur R Gayen; Jose Pablo Miramontes-Gonzalez; C Makena Hightower; Maja Mustapic; Manjula Mahata; Chun-Teng Huang; Vivian Y Hook; Sushil K Mahata; Sucheta Vaingankar; Daniel T O'Connor
Journal:  J Neurochem       Date:  2013-11-25       Impact factor: 5.372

9.  Monitoring CSF proteome alterations in amyotrophic lateral sclerosis: obstacles and perspectives in translating a novel marker panel to the clinic.

Authors:  Nils von Neuhoff; Tonio Oumeraci; Thomas Wolf; Katja Kollewe; Peter Bewerunge; Boris Neumann; Benedikt Brors; Johannes Bufler; Ulrich Wurster; Brigitte Schlegelberger; Reinhard Dengler; Marc Zapatka; Susanne Petri
Journal:  PLoS One       Date:  2012-09-06       Impact factor: 3.240

10.  A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer's disease.

Authors:  Tobias Skillbäck; Niklas Mattsson; Karl Hansson; Ekaterina Mirgorodskaya; Rahil Dahlén; Wiesje van der Flier; Philip Scheltens; Floor Duits; Oskar Hansson; Charlotte Teunissen; Kaj Blennow; Henrik Zetterberg; Johan Gobom
Journal:  Sci Rep       Date:  2017-10-17       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.